You are here
Home > 2021 > January > 12

Constellation Brands Completes Series of Transactions to Premiumize Portfolio With Sale of Paul Masson Grande Amber Brandy to Sazerac

VICTOR, N.Y., Jan. 12, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has closed its sale of the Paul Masson Grande Amber Brandy brand, related inventory, and interests in certain contracts to Sazerac for approximately $265 million, subject to certain post-closing adjustments. “The closure […]

Rapid Micro Biosystems Hires Chief Operating Officer

LOWELL, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, the leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the appointment of John Wilson as Chief Operating Officer reporting directly to the company’s CEO, Robert Spignesi. In this newly created role, John will be responsible for quality, supply chain and […]

Berkeley Lights Launches Opto Plasma B Discovery 4.0 to Accelerate Therapeutic Antibody Discovery Against Difficult Targets

EMERYVILLE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the Opto™ Plasma B Discovery 4.0 workflow. Opto Plasma B Discovery 4.0 is the industry’s premier antibody discovery workflow by advancing from B cells to lead molecules in just 1 week. This workflow enables […]

SweeGen Announces Successful Scale-up of Bestevia® Reb N

Further expands the sweet taste solution toolbox for tackling sugar reduction. Rancho Santa Margarita, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) — SweeGen is making possible a healthier, more guilt-free, and sweeter world with the commercialization of Bestevia® Rebaudioside N (Reb N), a special zero-calorie, highly sought-after natural stevia sweetener. Reb N is a naturally occurring […]

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study […]

Top